Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Advances in Therapy|June 9, 2022
Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-AnalysisRobert P Finger, Natalie Dennis, Rita Freitas, et al.
Journal of Clinical Pharmacology|September 30, 2011
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulationThorsten Lehr, Sebastian Haertter, Karl-Heinz Liesenfeld, et al.
COPD|April 17, 2018
Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL StudyKonstantinos Kostikas, Maryam Aalamian-Mattheis, Veronica Anna Pagano, et al.
Thrombosis and Haemostasis|March 31, 2010
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activityJoanne van Ryn, Joachim Stangier, Sebastian Haertter, et al.
Thrombosis and Haemostasis|February 10, 2012
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practiceMenno V Huisman, Gregory Y H Lip, Hans-Christoph Diener, et al.
Chest|May 20, 2019
Differences in COPD Exacerbation Risk Between Women and Men: Analysis From the UK Clinical Practice Research Datalink DataDaiana Stolz, Konstantinos Kostikas, Emil Loefroth, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 26, 2012
Quality of INR control and outcomes following venous thromboembolismArlene M Gallagher, Frank de Vries, Jonathan M Plumb, et al.
The American Journal of Cardiology|August 9, 2014
Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroupsAndreas Clemens, Siyang Peng, Sarah Brand, et al.
Thrombosis Research|May 23, 2016
Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacementCharles-Marc Samama, Nadia Rosencher, Eva Kleine, et al.
Current Eye Research|February 18, 2020
Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo DataHansjürgen Agostini, Zufar Mulyukov, Miltiadis Tsilimbaris, et al.
Pageof 9